Skip to main content
. 2019 Apr 14;44(4):502–510. doi: 10.1111/coa.13335

Figure 1.

Figure 1

Bacterial‐derived immunomodulator in the prevention of acute tonsillitis (Reprinted from Bitar & Saade, Copyright © 2013, with permission from Elsevier).57 “Total response” was defined as a >50% decrease in acute tonsillitis episodes at the end of treatment (ie 6 months); “partial response” was defined as a ≤50% decrease in acute tonsillitis episodes at the end of treatment. The immunomodulator used was OM‐85